No Data
No Data
Zhejiang Cheng Yi Pharmaceutical (603811.SH): The government plans to reclaim related land and affiliated assets of its Jiangsu subsidiary for 127 million yuan.
Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that its subsidiary, Jiangsu Chengyi Pharmaceutical Co., Ltd. ('Jiangsu Chengyi'),...
Zhejiang Cheng Yi Pharmaceutical (603811.SH) annual equity distribution in 2023: distribute 0.2 yuan per share, with June 7 as the record date.
Zhejiang Cheng Yi Pharmaceutical (603811.SH) released the implementation announcement of 2023 annual equity distribution, and the profit distribution this time is based on ...
Chengyi Pharmaceutical (603811.SH): Net profit of 32.685 million yuan in the first quarter, down 17.77% year on year
On April 25, Ge Longhui Pharmaceutical (603811.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 153 million yuan, an increase of 3.54%; net profit attributable to shareholders of listed companies was 32.685 million yuan, a year-on-year decrease of 17.77%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 308.902 million yuan, a year-on-year decrease of 20.40%; and basic earnings per share were 0.1 yuan.
Sincerity Pharmaceutical (603811.SH): Lidocaine hydrochloride injection passed generic drug consistency evaluation
On April 3, Ge Longhui Pharmaceutical (603811.SH) announced that it has received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration. The lidocaine hydrochloride injection (specification: 5ml: 0.1 g) produced by the company has passed the consistent evaluation of the quality and efficacy of generic drugs. Lidocaine hydrochloride injection is a local anesthetic and an antiarrhythmic drug.
Sincerity Pharmaceutical (603811.SH): The controlling shareholders' concerted actions increased their total shareholding by 1.05%
On March 7, Gelonghui Pharmaceutical (603811.SH) announced that as of the disclosure date of this announcement, the controlling shareholders' concerted actions increased their holdings by a total of 3,424,722 shares, accounting for 1.05% of the company's total share capital.
Gelonghui announcement selection | Haiguang Information: plans to spend 300 million yuan to 500 million yuan to buy back shares; Wehead: The company is not involved in Wensheng video technology and products
[Market Hot Topics] Weihai (301318.SZ): The company is not involved in the announcement of Wensheng Video Technology and the product VeHead (301318.SZ). The company is mainly engaged in R&D, production, sales and related technical services of audio and video communication equipment such as high-definition and ultra-high-definition video conferencing cameras, video conferencing terminals, conference microphones, etc. The company is not involved in Wensheng's video technology and products, and has not been involved in the AI big model business recently. Krei Electromechanical (603960.SH): Performance growth is mainly based on the original business, and there have been no significant changes in the performance growth basis. Krei Electromechanical (603960.SH) Co., Ltd.
No Data